Maravai LifeSciences (NASDAQ:MRVI) Trading Down 8.9% – What’s Next?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price was down 8.9% on Wednesday . The stock traded as low as $3.45 and last traded at $3.46. Approximately 339,664 shares traded hands during trading, a decline of 69% from the average daily volume of 1,078,739 shares. The stock had previously closed at $3.80.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MRVI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Wells Fargo & Company boosted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $5.25.

Maravai LifeSciences Price Performance

The firm has a market capitalization of $876.05 million, a P/E ratio of -4.09 and a beta of 0.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. The stock has a 50 day moving average of $3.63 and a two-hundred day moving average of $3.09.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The business had revenue of $41.63 million during the quarter, compared to analyst estimates of $49.02 million. Sell-side analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In other news, Director Gregory T. Lucier purchased 48,528 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were purchased at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the purchase, the director directly owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. The trade was a 45.53% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernd Brust bought 216,212 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average price of $3.25 per share, with a total value of $702,689.00. Following the completion of the purchase, the chief executive officer directly owned 466,771 shares of the company’s stock, valued at $1,517,005.75. This represents a 86.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 566,771 shares of company stock worth $1,880,244. 2.11% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently bought and sold shares of the business. Mirabella Financial Services LLP boosted its stake in Maravai LifeSciences by 0.3% in the second quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company’s stock worth $9,038,000 after purchasing an additional 10,049 shares in the last quarter. Monaco Asset Management SAM raised its stake in shares of Maravai LifeSciences by 315.0% in the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after acquiring an additional 2,775,372 shares during the last quarter. Geode Capital Management LLC raised its position in Maravai LifeSciences by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company’s stock worth $7,193,000 after purchasing an additional 319,679 shares during the last quarter. Tejara Capital Ltd lifted its holdings in Maravai LifeSciences by 26.4% during the 3rd quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company’s stock worth $7,041,000 after buying an additional 511,992 shares in the last quarter. Finally, Royce & Associates LP increased its stake in shares of Maravai LifeSciences by 38.0% in the 3rd quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock valued at $5,056,000 after buying an additional 484,908 shares during the period. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.